Innovent Biologics

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings

by

ROCKVILLE, Md. and SUZHOU, China, May 16, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announces that about 30 accepted abstracts of clinical data from multiple trials in relation to … Read more

Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma

by

ROCKVILLE, Md. and SUZHOU, China, May 14, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted … Read more